Business Wire

Cleareye.ai Announces J.P. Morgan’s Compliance Go-Live on the ClearTrade® Platform

21.4.2023 10:00:00 EEST | Business Wire | Press release

Share

Building off the momentum of the strategic alliance announcement last September, Cleareye.ai has continued its collaboration with J.P.Morgan Trade and Working Capital, which went live with ClearTrade® Compliance module in January. ClearTrade® Compliance automates the identification of the high-risk characteristics of transactions and, in an automated manner, aids users in the assessment of red flags and red flag management. It comes pre-integrated with external data providers for Vessel and Container Tracking, Bill of Lading Validation, and the identification of military & dual-use goods. This reduces risks for banks and increases efficiency and organizational controls, allowing banks to uplift global markets to higher standards without the corresponding increase in cost.

ClearTrade® is a comprehensive trade finance software suite that future proofs the trade operations and technology of banks through its three-module offering of Digitization, Compliance and Auto Doc Exam.

  • The Digitization module uses ICR/OCR and NLP to extract information found in documents and map data directly to a bank’s back-office system, allowing for operational efficiencies and potentially improved sanctions screening.
  • The Compliance module uses the data extracted from the digitization module & applies a series of red flag and vessel & container checks that provides information to help better control and navigate risks associated with each transaction.
  • The Automated Document Examination module uses advanced technologies to interpret and identify rules and conditions while validating against the presentation documents to optimize processing for trade operations.

The ClearTrade® platform has allowed for faster and more accurate document handling. The platform’s powerful image processing and data extraction provides significantly higher accuracy and confidence, to the tune of over 90%. This eliminates manual processes and allows data injection into a bank’s back-office system, improving the operational efficiency and transaction turnaround time.

Using the ClearTrade® platform, J.P.Morgan has accelerated its journey to future proof its trade finance operations, with plans to further uplift and roll out the platform globally.

James Fraser, Global Head of Trade for JPMorgan Payments says: “As our industry continues to change moving beyond the COVID pandemic, we have even more reason to focus on the digitization of trade. Cleareye’s ClearTrade® platform offers customization to streamline the manual and paper-heavy processes associated with due diligence. The strategic alliance between both J.P. Morgan and Cleareye will allow Cleareye to bring automated straight through processing to banks across the globe.”

Mariya George, CEO for Cleareye, states: “With our strategic alliance with J.P. Morgan, Cleareye is focused on revolutionizing the fintech and regtech markets. ClearTrade® not only helps streamline trade transactions, but also brings together data from global sources to enable banks make confident decisions for safe, efficient and lawful movement of trade, reducing Trade Based Money Laundering risk while meeting the changing regulatory needs.”

For any inquiries regarding this announcement or Cleareye.ai’s strategic alliance with J.P.Morgan, please reach out to your Cleareye.ai sales representative for more information or visit our website www.cleareye.ai

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mike Barbary
contact@cleareye.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience23.2.2026 16:13:00 EET | Press release

Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95th anniversary celebrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/ The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience “From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-famous Observatory, a private party room with a Ghirardelli sundae chef, Empire State Building party

CoolMPS™ 600: Accurate and Affordable Long MPS/NGS Reads on a Mid-Throughput Platform23.2.2026 16:00:00 EET | Press release

Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is utilizing the company’s proprietary antibody-based CoolMPS™ chemistry combined with DNBSEQ™, a real PCR-free DNA nanoarray technology. Separately, Swiss Rockets AG announced that it has entered into a definitive agreement to acquire 100% ownership of Complete Genomics. CoolMPS 600 enables cost-effective extended single-end sequencing to 600 bases (SE600) while maintaining high base accuracy. The system is designed to support advanced whole-genome sequencing (WGS) with improved mapping accuracy across complex genomic regions, including better detection of structural variants. It also enables full length transcriptomes and more infor

Xsolla Co-Sponsors Gamescom Dev Leadership Summit in Lisbon, Bringing Together Gaming Industry Leaders to Shape the Future of Game Development23.2.2026 16:00:00 EET | Press release

Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its co-sponsorship of the Gamescom Dev Leadership Summit Lisbon, taking place February 24-26 at SUD Lisboa in Portugal. The event brings together gaming industry executives, studio founders, and business leaders to explore opportunities and innovations shaping the future of game development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223253705/en/ Graphic: Xsolla As part of its sponsorship, Xsolla will host the summit's Wednesday evening networking dinner and co-moderate a strategic roundtable session focused on business models and sustainable growth in the gaming industry. "We're seeing incredible innovation from studios across Europe as they build more direct relationships with their players and explore new ways to grow their businesses," said Berkley Egenes, Chief Marketing & Growth Officer at

Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 15:08:00 EET | Press release

Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223465174/en/ Under the terms of the multi-year agreement, Quiver will receive an undisclosed advance payment and support for defined research activities along with additional licensing fees granting Angelini Pharma exclusive access to collaboration-generated data during the research term. Quiver is also eligible to receiv

Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 15:00:00 EET | Press release

Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DISA IL authorized Cyber Exposure Management Platform. The company previously achieved FedRAMP Mo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye